Chris joined Aurora in 2003 and became a Partner in 2007.
Chris focuses on biopharmaceutical and medical device
opportunities and brings a broad spectrum of business,
clinical and scientific expertise to Aurora's investments
in these sectors. Chris led or co-led syndicated
investments in Cardioxyl Pharmaceuticals, Hyberbranch
Medical, and Neotropix, and led Auroras's investments in
Cardiofocus and Paringenix.
Prior to joining Aurora, Chris trained in general
surgery at Brigham and Women's Hospital/Harvard
Medical School where he was involved in the medical
and surgical care of transplant, trauma, vascular,
cardiac and general surgical patients. He has over
seven years of clinical experience in both academic
and community hospital practices, and is a licensed
physician in North Carolina.
Chris also has significant basic science research
experience primarily in signal transduction, including
work on the molecular biology and genetics of
apoptosis, and the transcriptional regulation of
Interleukin-2 in human T-cells.
Chris Previously worked with Arthur D. Little/Decision
Resources, providing industry and technology analysis
to biotechnology and pharmaceutical companies.
Additionally, while attending business school, Chris
worked in Corporate Development at Genzyme.
Chris received a B.A. in Biology from Harvard
University, his M.D. from Stanford University School
of Medicine and an MBA from Harvard Business School.
Chris serves on the boards of Cardiofocus, Cardioxyl
Pharmaceuticals, Hyperbranch Medical Technologies,
Neotropix and ParinGenix, and serves as an observer on
the boards of Aldagen, Argos, Metastatix and Regado.
Chris also serves on the boards of the Johns Hopkins
Technology Alliance, The University of Maryland
Baltimore Commercialization Advisory Board and The
Council for Entrepreneurial Development (CED).